Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax Quadrivalent VLP Influenza Vaccine in Healthy Adults
NCT01561768Phase 2Completed
- Sponsor
- Novavax
- Start
- Mar 2012
- Primary completion
- Jan 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of quadrivalent influenza vaccine candidate in influenza (5 arms), sponsored by Novavax. Primary endpoints: Immunogenicity based on Hemagglutination Inhibition (HAI) responses at Day 21 and Number of Solicited and Unsolicited Adverse Events at 6 months. Started Mar 2012; status: completed.
02
Drugs
quadrivalent influenza vaccine candidate
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01561768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561768.